2857 related articles for article (PubMed ID: 6607324)
1. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
[TBL] [Abstract][Full Text] [Related]
2. Combined interferon and vinblastine treatment of advanced melanoma: evaluation of the treatment results and the effects of the treatment on immunological functions.
Kellokumpu-Lehtinen P; Nordman E; Toivanen A
Cancer Immunol Immunother; 1989; 28(3):213-7. PubMed ID: 2784356
[TBL] [Abstract][Full Text] [Related]
3. The treatment of cancer patients with human lymphoblastoid interferon. A comparison of two routes of administration.
Knost JA; Sherwin SA; Abrams PG; Ochs JJ; Foon KA; Williams R; Tuttle R; Oldham RK
Cancer Immunol Immunother; 1983; 15(2):144-8. PubMed ID: 6307500
[TBL] [Abstract][Full Text] [Related]
4. Decrease in the phagocytic activity of peripheral monocytes in patients treated with human interferon-alpha.
Einhorn S; Jarstrand C
Cancer Immunol Immunother; 1982; 13(3):149-52. PubMed ID: 6925979
[TBL] [Abstract][Full Text] [Related]
5. Application of a new method for detecting the phenotype of target binding cells.
Lindemann RA; Jenkins JA; Figlin RA; Golub SH
Cancer Immunol Immunother; 1987; 25(2):153-5. PubMed ID: 3311361
[TBL] [Abstract][Full Text] [Related]
6. Epidermotropic metastatic malignant melanoma simulating melanoma in situ. A report of 10 examples from two patients.
Abernethy JL; Soyer HP; Kerl H; Jorizzo JL; White WL
Am J Surg Pathol; 1994 Nov; 18(11):1140-9. PubMed ID: 7943535
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of the immunohistological state of the lymph nodes regional to a tumor].
Serov AA
Biull Eksp Biol Med; 1980 Feb; 89(2):196-8. PubMed ID: 6966167
[TBL] [Abstract][Full Text] [Related]
8. Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells.
Kaufmann R; Schafberg H; Rudroff C; Nowak G
Cancer; 1997 Dec; 80(11):2068-74. PubMed ID: 9392328
[TBL] [Abstract][Full Text] [Related]
9. The proteolytic potential of normal human melanocytes: comparison with other skin cells and melanoma cell lines.
Bizik J; Bessou S; Felnerova D; Vaheri A; Taïeb A
Pigment Cell Res; 1996 Oct; 9(5):255-64. PubMed ID: 9014212
[TBL] [Abstract][Full Text] [Related]
10. Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts.
Degen WG; Weterman MA; van Groningen JJ; Cornelissen IM; Lemmers JP; Agterbos MA; Geurts van Kessel A; Swart GW; Bloemers HP
Int J Cancer; 1996 Feb; 65(4):460-5. PubMed ID: 8621228
[TBL] [Abstract][Full Text] [Related]
11. [Peritumoral administered IL-2-induced tumor regression in melanoma. Pilot study].
Gutwald J; Groth W; Mahrle G
Hautarzt; 1994 Aug; 45(8):536-40. PubMed ID: 7960753
[TBL] [Abstract][Full Text] [Related]
12. Cell adhesion molecules acting between C6 glioma and endothelial cells.
Tamaki M; Aoyagi M; Morita I; Hirakawa K; Murota S
J Neurooncol; 1995; 24(2):181-8. PubMed ID: 7562005
[TBL] [Abstract][Full Text] [Related]
13. Difference in 3H-thymidine incorporation after irradiation between murine B16 melanoma and squamous cell carcinoma in vivo.
Furuse T; Kasuga T
Gan; 1983 Apr; 74(2):232-9. PubMed ID: 6862144
[TBL] [Abstract][Full Text] [Related]
14. Expression of MAGE genes in primary and metastatic cutaneous melanoma.
Brasseur F; Rimoldi D; Liénard D; Lethé B; Carrel S; Arienti F; Suter L; Vanwijck R; Bourlond A; Humblet Y
Int J Cancer; 1995 Nov; 63(3):375-80. PubMed ID: 7591235
[TBL] [Abstract][Full Text] [Related]
15. [The potentials of impulse laser radiation in treating I-stage melanomas of the skin].
Moskalik KG; Vagner RI; Kozlov AP
Vestn Khir Im I I Grek; 1996; 155(2):38-40. PubMed ID: 8966902
[TBL] [Abstract][Full Text] [Related]
16. Thiourea as a melanoma targeting agent.
Mårs U; Larsson BS
Melanoma Res; 1996 Apr; 6(2):113-20. PubMed ID: 8791268
[TBL] [Abstract][Full Text] [Related]
17. Impaired HLA-class-I stability in a sarcoma cell line which stimulates exclusively HLA-class-II-restricted autologous T cells.
Heike M; Schmitt U; Höhne A; Huber C; Meyer zum Büschenfelde KH
Int J Cancer; 1996 Sep; 67(5):743-8. PubMed ID: 8782668
[TBL] [Abstract][Full Text] [Related]
18. Changes in plasma 5-S-cysteinyldopa concentration in B16 melanoma-bearing mice treated with interferon-beta or dacarbazine.
Hasegawa K; Inoue S; Wakamatsu K; Ito S; Fujita K; Ishihara K
Melanoma Res; 1993 Oct; 3(5):377-80. PubMed ID: 8292896
[TBL] [Abstract][Full Text] [Related]
19. [Is UV-A a cause of malignant melanoma?].
Moan J
Tidsskr Nor Laegeforen; 1994 Mar; 114(8):935-8. PubMed ID: 8191472
[TBL] [Abstract][Full Text] [Related]
20. [Quantitative analysis of nucleolar organizer regions in nevi and melanomas].
Dujela N
Lijec Vjesn; 1993; 115(7-8):241-3. PubMed ID: 8139368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
